

Article in Japanese
A case of KRAS mutation-positive invasive mucus-producing lung adenocarcinoma with high serum CA19-9 levels
Yuki Seikea Kazuyoshi Watanabea Task Iwabuchia Tamami Sakaia Seiji Yanob
aDepartment of Respiratory Medicine, Japan Community Health Care Organization Kanazawa Hospital
bDepartment of Respiratory Medicine, Kanazawa University Hospital
The patient, a 77-year-old man, was diagnosed with invasive mucus-producing lung adenocarcinoma (cT4N3M1b stage IVA, KRAS G12C positive) and started chemotherapy with carboplatin, pemetrexed, and pembrolizumab. The tumors markedly reduced in size. Pembrolizumab-containing chemotherapy was effective in KRAS mutation-positive invasive mucus-producing lung adenocarcinoma.
Invasive mucinous adenocarcinoma KRAS G12C Pembrolizumab
Received 16-Apr-24 / Accepted 28-Jun-24
AJRS, 13(5): 213-217, 2024